A Prospective, Randomised Study to Assess Safety, Changes in Platelet Reactivity, Plasma Cardiac Biomarkers, Immunological and Metabolic Parameters in HIV-1 Infected Subjects Undergoing a Switch in Antiretroviral Therapy.

Trial Profile

A Prospective, Randomised Study to Assess Safety, Changes in Platelet Reactivity, Plasma Cardiac Biomarkers, Immunological and Metabolic Parameters in HIV-1 Infected Subjects Undergoing a Switch in Antiretroviral Therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2016

At a glance

  • Drugs Maraviroc (Primary) ; Abacavir; Didanosine; Peptide hydrolase inhibitors
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms SMASH
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 31 May 2012 United Kingdom Clinical Research Network reports accrual to date changed from 42% to 45%.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top